Copaxone

Pharma

Teva takes $215M hit from currency effects

Even as Teva CEO Kåre Schultz works to usher the company through a mass of opioid litigation and a heavy debt load, he’s now facing a new challenge.  
Eric Sagonowsky Nov 3, 2022 9:25am

The early findings of an EC investigation look bad for Teva

Oct 10, 2022 9:36am
Podcast

'The Top Line' podcast: Layoff trends, generics sales and more

Jul 22, 2022 6:00am

J&J's Momenta calls infringement against Mylan and its partners

May 25, 2022 8:59am

Teva faces $100M claim by Israel over Copaxone royalties: report

May 11, 2022 8:50am

Teva CEO Schultz's pay falls 7% to $14.7M amid sales slump

Mar 17, 2022 7:38pm